A feasibility study to evaluate early treatment response of brain metastases one week after stereotactic radiosurgery using perfusion weighted imaging.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
17
07
2020
accepted:
20
10
2020
entrez:
3
11
2020
pubmed:
4
11
2020
medline:
21
1
2021
Statut:
epublish
Résumé
To explore if early perfusion-weighted magnetic resonance imaging (PWI) may be a promising imaging biomarker to predict local recurrence (LR) of brain metastases after stereotactic radiosurgery (SRS). This is a prospective pilot study of adult brain metastasis patients who were treated with SRS and imaged with PWI before and 1 week later. Relative cerebral blood volume (rCBV) parameter maps were calculated by normalizing to the mean value of the contralateral white matter on PWI. Cox regression was conducted to explore factors associated with time to LR, with Bonferroni adjusted p<0.0006 for multiple testing correction. LR rates were estimated with the Kaplan-Meier method and compared using the log-rank test. Twenty-three patients were enrolled from 2013 through 2016, with 22 evaluable lesions from 16 patients. After a median follow-up of 13.1 months (range: 3.0-53.7), 5 lesions (21%) developed LR after a median of 3.4 months (range: 2.3-5.7). On univariable analysis, larger tumor volume (HR 1.48, 95% CI 1.02-2.15, p = 0.04), lower SRS dose (HR 0.45, 95% CI 0.21-0.97, p = 0.04), and higher rCBV at week 1 (HR 1.07, 95% CI 1.003-1.14, p = 0.04) had borderline association with shorter time to LR. Tumors >2.0cm3 had significantly higher LR than if ≤2.0cm3: 54% vs 0% at 1 year, respectively, p = 0.008. A future study to confirm the association of early PWI and LR of the high-risk cohort of lesions >2.0cm3 is estimated to require 258 patients. PWI at week 1 after SRS may have borderline association with LR. Tumors <2.0cm3 have low risk of LR after SRS and may be low-yield for predictive biomarker studies. Information regarding sample size and potential challenges for future imaging biomarker studies may be gleaned from this pilot study.
Sections du résumé
BACKGROUND
To explore if early perfusion-weighted magnetic resonance imaging (PWI) may be a promising imaging biomarker to predict local recurrence (LR) of brain metastases after stereotactic radiosurgery (SRS).
METHODS
This is a prospective pilot study of adult brain metastasis patients who were treated with SRS and imaged with PWI before and 1 week later. Relative cerebral blood volume (rCBV) parameter maps were calculated by normalizing to the mean value of the contralateral white matter on PWI. Cox regression was conducted to explore factors associated with time to LR, with Bonferroni adjusted p<0.0006 for multiple testing correction. LR rates were estimated with the Kaplan-Meier method and compared using the log-rank test.
RESULTS
Twenty-three patients were enrolled from 2013 through 2016, with 22 evaluable lesions from 16 patients. After a median follow-up of 13.1 months (range: 3.0-53.7), 5 lesions (21%) developed LR after a median of 3.4 months (range: 2.3-5.7). On univariable analysis, larger tumor volume (HR 1.48, 95% CI 1.02-2.15, p = 0.04), lower SRS dose (HR 0.45, 95% CI 0.21-0.97, p = 0.04), and higher rCBV at week 1 (HR 1.07, 95% CI 1.003-1.14, p = 0.04) had borderline association with shorter time to LR. Tumors >2.0cm3 had significantly higher LR than if ≤2.0cm3: 54% vs 0% at 1 year, respectively, p = 0.008. A future study to confirm the association of early PWI and LR of the high-risk cohort of lesions >2.0cm3 is estimated to require 258 patients.
CONCLUSIONS
PWI at week 1 after SRS may have borderline association with LR. Tumors <2.0cm3 have low risk of LR after SRS and may be low-yield for predictive biomarker studies. Information regarding sample size and potential challenges for future imaging biomarker studies may be gleaned from this pilot study.
Identifiants
pubmed: 33141861
doi: 10.1371/journal.pone.0241835
pii: PONE-D-20-22243
pmc: PMC7608872
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0241835Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR002345
Pays : United States
Organisme : NINDS NIH HHS
ID : P30 NS098577
Pays : United States
Organisme : NIBIB NIH HHS
ID : R01 EB009352
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000448
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Neurosurg. 2013 Nov;119(5):1139-44
pubmed: 23971958
JAMA. 2006 Jun 7;295(21):2483-91
pubmed: 16757720
Clin Oncol (R Coll Radiol). 2014 Nov;26(11):704-12
pubmed: 25023291
Clin Trials. 2005;2(2):182-92
pubmed: 16279140
Neuroinformatics. 2016 Jul;14(3):305-17
pubmed: 26910516
J Clin Oncol. 2011 Jan 10;29(2):134-41
pubmed: 21041710
Biomed Res Int. 2014;2014:598052
pubmed: 24877119
Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):452-64
pubmed: 12957257
Neuro Oncol. 2016 Aug;18(8):1043-65
pubmed: 27382120
J Clin Oncol. 2018 Feb 10;36(5):483-491
pubmed: 29272161
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Lancet Oncol. 2009 Nov;10(11):1037-44
pubmed: 19801201
AJNR Am J Neuroradiol. 2007 Jun-Jul;28(6):1078-84
pubmed: 17569962
JAMA. 2016 Jul 26;316(4):401-409
pubmed: 27458945
Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):656-61
pubmed: 22898384
Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):876-85
pubmed: 16298499
J Clin Oncol. 2014 Dec 1;32(34):3810-6
pubmed: 25349290
Radiology. 2003 Jul;228(1):193-9
pubmed: 12832582
Radiology. 2010 Aug;256(2):575-84
pubmed: 20529987
Radiology. 2002 Apr;223(1):11-29
pubmed: 11930044
J Neurosurg. 2018 May 4;130(3):804-811
pubmed: 29726782
Radiology. 2002 Mar;222(3):715-21
pubmed: 11867790
Neuroimage. 2012 Aug 15;62(2):782-90
pubmed: 21979382
J Natl Cancer Inst. 2007 Oct 3;99(19):1441-54
pubmed: 17895480
AJR Am J Roentgenol. 2018 Dec;211(6):1332-1341
pubmed: 30240297
Neuro Oncol. 2015 Jun;17(6):895-900
pubmed: 25526734
Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):485-91
pubmed: 22331000
J Clin Oncol. 2013 Jan 1;31(1):65-72
pubmed: 23213105
Cell Cycle. 2010 Aug 1;9(15):3012-21
pubmed: 20714216
J Neurosurg. 2018 Aug;129(2):366-382
pubmed: 28937324
AJNR Am J Neuroradiol. 2005 Jun-Jul;26(6):1446-54
pubmed: 15956514